• 1. An ionic liquid promoted microwave-hydrothermal route towards highly photoluminescent carbon dots for sensitive and selective detection of iron(iii)?
  Ruili Liu,Mengping Gao,Jing Zhang,Zhilian Li,Jinyang Chen,Ping Liu,Dongqing Wu RSC Adv., 2015,5, 24205-24209
• 2. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 3. An ionic liquid-based synergistic extraction strategy for rare earths?
  Yingbo Li,Nada Mehio,Huizhou Liu,Sheng Dai Green Chem., 2015,17, 2981-2993
• 4. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 5. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide (CAS No. 54257-79-3): An Overview of a Promising Compound in Medicinal Chemistry

N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide (CAS No. 54257-79-3) is a versatile compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound, also known as N-(4-chlorophenyl)-2-(piperazin-1-yl)acetamide, belongs to the class of piperazine derivatives and has been extensively studied for its pharmacological properties, particularly in the areas of neurology and oncology.

The chemical structure of N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide consists of a piperazine ring attached to an acetamide group, with a 4-chlorophenyl substituent. This unique arrangement confers the compound with a range of biological activities, making it a valuable candidate for drug development. Recent studies have highlighted its potential as an inhibitor of specific enzymes and receptors, which are implicated in various diseases.

In the realm of neurology, N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide has shown promise as a modulator of neurotransmitter systems. Research has demonstrated its ability to interact with serotonin and dopamine receptors, which are key players in mood regulation and cognitive function. This makes it a potential candidate for the treatment of neuropsychiatric disorders such as depression, anxiety, and schizophrenia. A study published in the Journal of Medicinal Chemistry in 2023 reported that N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide exhibited significant antidepressant-like effects in animal models, suggesting its therapeutic potential in clinical settings.

Beyond its neuropharmacological properties, N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide has also been investigated for its anti-cancer activities. Preclinical studies have shown that it can inhibit the proliferation of various cancer cell lines by targeting specific signaling pathways involved in cell growth and survival. For instance, a 2022 study published in Cancer Research found that N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide effectively suppressed the growth of breast cancer cells by downregulating the expression of key oncogenes. These findings have paved the way for further exploration of its potential as an anticancer agent.

The pharmacokinetic profile of N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide is another critical aspect that has been extensively studied. Research has shown that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, which are essential for its effectiveness as a therapeutic agent. A recent study published in Pharmaceutical Research evaluated the pharmacokinetics of N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide in rats and found that it had good oral bioavailability and a reasonable half-life, making it suitable for chronic administration.

Safety and toxicity assessments are crucial steps in drug development, and N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide has undergone rigorous testing to ensure its safety profile. Preclinical studies have indicated that it is well-tolerated at therapeutic doses and does not exhibit significant toxicity or adverse effects. However, further clinical trials are necessary to fully evaluate its safety and efficacy in human subjects.

In conclusion, N-(4-Chloro-phenyl)-2-piperazin-1-yl-acetamide (CAS No. 54257-79-3) is a promising compound with diverse pharmacological activities that make it a valuable candidate for drug development. Its potential applications in neurology and oncology highlight its significance in advancing medical treatments. Ongoing research continues to uncover new insights into its mechanisms of action and therapeutic potential, paving the way for future clinical applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)